Latent Labs

Latent Labs is a frontier AI research company building generative models that capture the fundamental principles of biology. The company's mission is to make biology programmable in order to transform health and sustainability for the benefit of all. By developing cutting-edge generative AI, Latent Labs empowers partners to gain unprecedented control over molecular biology — enabling the creation of new antibodies, optimization of existing enzymes, and advancement of genetic engineering applications.

The founding team at Latent Labs brings exceptional pedigree to the field, having co-developed DeepMind's Nobel Prize-winning AlphaFold models. The company operates out of London and San Francisco and is backed by leading investors including Radical Ventures, Sofinnova Partners, 8VC, Pillar VC, Kindred Capital, Isomer, and Flying Fish. Notable angel investors include Google Chief Scientist Jeff Dean, Anthropic CEO Dario Amodei, and ElevenLabs founder Mati Staniszewski.

Frontier Models

• Latent-Y: The first lab-validated autonomous AI agent for drug design at scale. Latent-Y represents a significant milestone as a fully agentic system capable of driving drug design workflows autonomously.
• Latent-X2: A frontier model specifically designed for drug-like antibodies with low immunogenicity, validated in human panels. Latent-X2 is engineered to support the development of safer, more effective antibody therapeutics.
• Latent-X: An atom-level frontier model for de novo protein binder design, enabling the creation of entirely new protein binders from scratch with atomic precision.

Core Capabilities

• Generative AI models that operate across the full spectrum of molecules of life, including proteins and antibodies.
• De novo molecular design, allowing partners to engineer entirely new biological entities rather than modifying existing ones.
• Autonomous agentic workflows for drug design, reducing the need for manual intervention in complex molecular design pipelines.
• Optimization of existing enzymes and support for genetic engineering applications.
• Lab-validated outputs, bridging the gap between computational predictions and real-world experimental results.

Team and Partnerships

• The company actively recruits across machine learning, computational protein design, reasoning workflows, and software engineering disciplines.
• Positions are available in both London and San Francisco, reflecting the company's international presence.
• Latent Labs works with partners seeking breakthrough generative AI capabilities for molecular biology research and drug development.
• Partnership, media, and general enquiries are welcomed directly through the company's contact channels.

Latent Labs is positioned at the intersection of frontier AI and life sciences, translating advances in generative modeling into practical tools for drug discovery, protein engineering, and beyond. The company continues to expand its model portfolio and partner ecosystem as it pursues its mission of making biology fully programmable.